Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
70
resultados
Última actualización
13/09/2025 [07:47:00]
Resumen de: WO2025188949A1
A sample collection device having a sample container, a solid phase binding material, and a container sealing component is presented. The sample container may have a housing that forms an opening for receiving a sample, and that encloses a space for holding the sample. The solid phase binding material may be disposed within the space enclosed by the housing of the sample container and may be adapted, when the sample contains an analyte, to bind specifically to the analyte. The container sealing component may be removably attachable to the sample container at the opening thereof, and may be adapted, when attached to the sample container, to form a seal around the opening of the sample container.
Resumen de: US2025283897A1
Disclosed is a method for diagnosing Alzheimer's disease based on deep learning and an SAM, and a SERS substrate therefor. According to an embodiment, a deep learning and self-assembled monolayer (SAM)-based Alzheimer's disease diagnosing method performed by a computer device includes preparing a three-dimensional (3D) surface-enhanced Raman scattering (SERS) substrate by continuously stacking nanowire layers arranged in parallel by using a nanotransfer printing technology, forming an SAM on the 3D SERS substrate, and obtaining a Raman signal by applying a metabolite solution on the 3D SERS substrate having the SAM on a surface.
Resumen de: US2025283892A1
The present invention relates to a method for the diagnosis of Alzheimer's Disease, comprising the steps of (i) determining the level of antibodies against YB-1 in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without Alzheimer's Disease, wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative of Alzheimer's Disease in the subject.
Resumen de: WO2024097164A1
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Resumen de: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Resumen de: US2025277799A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Resumen de: US2025277798A1
The invention relates to skin biomarkers, and in particular, to skin biomarkers for diagnosing and prognosing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as diagnostic and prognostic methods and kits for these conditions. The invention also provides methods of treating neurodegenerative disorders. The invention further provides the use of biomarkers in the skin for skin aging (biological & chronological), and kits for detecting and quantifying skin aging, and also methods for treating, preventing or slowing down skin aging.
Resumen de: AU2025220690A1
A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and 5 homocysteine, independently in one or more samples obtained from the subject. A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and 5 homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject. ug m e t h o d f o r i d e n t i f y i n g p r e - d i s p o s i t i o n t o c o g n i t i v e d e c l i n e i n a s u b j e c t , t h e m e t h o d u g c o m p r i s i n g d e t e r m i n i n g l e v e l s o f : ( a ) o m e g a - f a t t y a c i d s , a n d v i t a m i n o r a m e t a b o l i t e t h e r e o f ; ( b ) o m e g a - f a t t y a c i d s , a n d h o m o c y s t e i n e ; ( c ) v i t a m i n o r a m e t a b o l i t e t h e r e o f , a n d h o m o c y s t e i n e ; o r ( d ) o m e g a - f a t t y a c i d s , v i t a m i n o r a m e t a b o l i t e t h e r e o f , a n d h o m o c y s t e i n e , i n d e p e n d e n t l
Resumen de: WO2025182761A1
Provided is a method for detecting GFAP in a sample by immunoassay, the method including a first step for forming a complex of a first antibody and GFAP, and a second step for forming a complex of a second antibody and GFAP, the first antibody binding to a region consisting of amino acids at positions 111 to 115 in the amino acid sequence of GFAP.
Resumen de: WO2025181335A1
The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.
Resumen de: US2025277268A1
Embodiments of the present disclosure herein relate to a method for providing information for predicting a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and/or a positron emission tomography (PET)-positive risk group for amyloid β deposition, based on European population data. In an embodiment, the method makes it possible to accurately predict a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and/or a positron emission tomography (PET)-positive risk group for amyloid β deposition by using only at least 11 single-nucleotide polymorphisms, and the ability to predict the risk groups is further enhanced when up to and at most 39 additional single-nucleotide polymorphisms are used.
Resumen de: KR20250129282A
본 발명은 루이소체병의 증상을 동반한 알츠하이머병 환자를 정상대조군과 구분하여 진단할 수 있는 영상 바이오 마커에 관한 것으로, 보다 상세하게는, 본 발명은 중뇌 흑색질의 도파민 운반체 섭취율(DAT-SN), 및 선조체 조가비핵의 조기 도파민 섭취율 대 지연 도파민 섭취율의 비율(E/D-PP)을 영상 바이오마커로 사용하여 정상대조군과 구별하여 루이소체병의 증상을 동반한 알츠하이머병 환자의 진단 정확도를 높이는 효과를 제공한다.
Resumen de: JP2024147610A
To provide antibodies for use in the treatment of neurodegenerative diseases, or pharmaceutical compositions thereof.SOLUTION: The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.SELECTED DRAWING: None
Resumen de: US2025271453A1
A protein antigen combination containing SERF2 and applications thereof in the field of biological detection are disclosed. The antigen combination for detecting autoantibodies can distinguish Alzheimer's disease (AD) from frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB), and the antigen combination at least includes protein fragments of SERF2. The new protein antigen composition can not only effectively identify patients with AD, but also effectively distinguish AD from FTD and DLB, enabling accurate identification of AD. It is of great importance in terms of diagnostic applications and research.
Resumen de: US2025270618A1
Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.
Resumen de: US2025268952A1
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.
Resumen de: US2025268982A1
Non-aggregating protein analogues of proteins involved in a proteinopathy, for example Alzheimer's disease, are provided. The protein has a beta-sheet aggregation domain, and the non-aggregating protein analogue has a beta-sheet destabilizing modification in the beta-sheet aggregation domain but substantially retains wild type protein function. The beta-sheet destabilizing modification can be a substitution of a naturally occurring amino acid for a non-naturally occurring amino acid. Methods of treating a proteinopathy using the non-aggregating protein analogues and methods of designing a non-aggregating protein analogue are provided.
Resumen de: WO2025179300A1
Methods, compositions, and kits are capable of detecting, identifying, diagnosing, prognosing, assessing, monitoring, and/or treating a neurological injury such as acute TBI and distinguishing geriatric TBI from conditions such as dementia, Alzheimer's Disease, Parkinson's disease and the like. Also disclosed are methods of testing elderly patients who have or are suspected of having traumatic brain injury using panels of biomarkers that distinguish TBI from dementia, and, optionally, treating such patients for TBI or dementia based upon the results of the biomarker tests.
Resumen de: US2025270301A1
The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to antibodies, specific for isolated recombinant peptides comprising an epitope from human tau 2N4R and to such antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.
Resumen de: CN119998661A
In a first aspect, the present invention relates to a method for identifying a subject suffering from or at risk of developing Alzheimer's dementia (AD), the method comprising: (a) determining in a first bodily fluid sample of the subject at least an amount of a compound having a mass of 110.0367 in grams/mole; (b) determining an amount of the same compound as in (a) in a second body fluid sample of the subject; (c) determining a change in the amount of the compound determined according to (a) compared to the corresponding amount of the compound determined according to (b); (d) analyzing the change determined in (c) using a computer-implemented prediction algorithm capable of predicting AD in the subject based on the compound, thereby identifying a subject having AD or at risk of developing Alzheimer's dementia if AD is predicted; wherein the first body fluid sample is obtained prior to administration of thietherazine or a pharmaceutically acceptable salt thereof, and the second body fluid sample is obtained after administration of thietherazine or a pharmaceutically acceptable salt thereof to the subject.
Resumen de: US2025262337A1
A method for detecting soluble oligomeric amyloid β in a subject is provided.
Resumen de: US2025262247A1
The disclosure provides methods and compositions related to microglial cell development and therapies in neuronal development.
Resumen de: US2025264482A1
The present specification discloses a composition, a system, and a method for predicting or diagnosing Alzheimer's disease, comprising a detecting agent of a B cell receptor clonotype specific to an Alzheimer's disease patient, and the composition according to one aspect of the present invention has an excellent effect in predicting or diagnosing Alzheimer's disease by simply using peripheral blood mononuclear cells isolated from a subject, in addition to methods such as MRI and PET scans using radioactive substances, by comprising a detecting agent of a B cell receptor (BCR) clonotype specific to an Alzheimer's disease patient.
Resumen de: CN119768689A
Use of a novel highly toxic amyloid oligomer A beta o * 3F as a target for diagnosis of early and mid-advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), A beta o * 3F is specifically bound by a 3F antibody, and exists in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived MCI patients, the Abeta oligomers have the advantages that the Abeta oligomers are high-toxicity oligomers, the levels of the Abeta oligomers are remarkably different in CSF, blood and/or brain tissues of AD patients, MCI patients and healthy old people, and the Abeta oligomers are super-toxicity oligomers, are the most major toxic components in A beta oligomer mixtures, have strong pathogenic effects and play a key role in occurrence and development of AD.
Nº publicación: US2025257318A1 14/08/2025
Solicitante:
NEW YORK STEM CELL FOUND INC [US]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
New York Stem Cell Foundation, Inc,
Icahn School of Medicine at Mount Sinai
Resumen de: US2025257318A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
BOPI
Sede Electrónica
